The problems with anticancer therapy are resistance and toxicity. From 3000 Cisplatin
derivatives tested as antitumor agents, most of them have been rejected, due to toxicity. The …

Background: ALK inhibitors have shown positive advance in the treatment of ALK+ NSCLC.
They have achieved better results in prolonging the progression free survival and improving …

Although well established for the treatment of certain hematologic malignancies,
maintenance therapy has only recently become a treatment paradigm for advanced non …

Pemetrexed has been widely used in patients with advanced non‐small cell lung cancer
(NSCLC). The clinical relevance of polymorphisms of folate pathway genes for pemetrexed …

Lung cancer remains the leading common cause of cancer-related death, with non-small-
cell lung cancer (NSCLC) accounting for 80% of all cases. To date, platinum-based doublet …

Purpose To establish a baseline for care and overall survival (OS) based upon
contemporary first-line treatments prescribed in the era before the introduction of immune …

Non-small cell lung cancer constitutes 85% to 90% of lung cancer and is the most common
cause of cancer death. Over the past 50 years, substantial progress has been made in all …

BACKGROUND First-line therapy for advanced non–small-cell lung cancer (NSCLC) that
lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor …

ABSTRACT EGFR-TKI therapy produces a dramatic clinical response in patients with
NSCLC harboring EGFR mutation. However, clinical outcomes should be improved further …

Introduction ROS1-rearranged NSCLC is classified as a distinct molecular subset of NSCLC
with a therapeutic target. ROS1 rearrangement is most often identified in never-smokers with …